1. Home
  2. ELDN vs INR Comparison

ELDN vs INR Comparison

Compare ELDN & INR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • INR
  • Stock Information
  • Founded
  • ELDN 2004
  • INR 2017
  • Country
  • ELDN United States
  • INR United States
  • Employees
  • ELDN N/A
  • INR N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • INR
  • Sector
  • ELDN Health Care
  • INR
  • Exchange
  • ELDN Nasdaq
  • INR NYSE
  • Market Cap
  • ELDN 178.4M
  • INR N/A
  • IPO Year
  • ELDN N/A
  • INR 2025
  • Fundamental
  • Price
  • ELDN $3.17
  • INR $17.03
  • Analyst Decision
  • ELDN Strong Buy
  • INR Strong Buy
  • Analyst Count
  • ELDN 1
  • INR 7
  • Target Price
  • ELDN $16.00
  • INR $27.43
  • AVG Volume (30 Days)
  • ELDN 150.4K
  • INR 229.8K
  • Earning Date
  • ELDN 05-20-2025
  • INR 01-01-0001
  • Dividend Yield
  • ELDN N/A
  • INR N/A
  • EPS Growth
  • ELDN N/A
  • INR N/A
  • EPS
  • ELDN N/A
  • INR N/A
  • Revenue
  • ELDN N/A
  • INR $259,022,000.00
  • Revenue This Year
  • ELDN N/A
  • INR $49.25
  • Revenue Next Year
  • ELDN N/A
  • INR $17.14
  • P/E Ratio
  • ELDN N/A
  • INR $21.32
  • Revenue Growth
  • ELDN N/A
  • INR 60.16
  • 52 Week Low
  • ELDN $2.00
  • INR $13.64
  • 52 Week High
  • ELDN $5.54
  • INR $23.00
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 48.82
  • INR N/A
  • Support Level
  • ELDN $2.85
  • INR N/A
  • Resistance Level
  • ELDN $3.51
  • INR N/A
  • Average True Range (ATR)
  • ELDN 0.25
  • INR 0.00
  • MACD
  • ELDN 0.01
  • INR 0.00
  • Stochastic Oscillator
  • ELDN 45.07
  • INR 0.00

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: